Tessa showcases preclinical promise of 'all-in-one' add-on to its cancer cell therapy, in march to the clinic

At Tessa Therapeutics, the big idea has been to adapt virus-specific T cells (VST) to target virally-associated tumors, and swarm cancer cells. Researchers believe these VSTs can be versatile, making superior CAR-Ts that can then be combined with an oncolytic virus and a checkpoint inhibition strategy.